Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- New Ocrevus Subcutaneous Injection Therapy Shows Promising Results in Multiple Sclerosis Treatmen
- Dutch Man Infected with COVID-19 for 613 Days Dies: Accumulating Over 50 Virus Mutations
Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients.
Tukysa (Tucatinib) and its parent drug ONT-993 have been detected in CSF and are directly proportional to the level in plasma.
The results of a phase 2 study (NCT03501979) examined the combined treatment of tucatinib (Tukysa), trastuzumab (Herceptin) and capecitabine (Xeloda) in HER2-positive breast cancer patients with pial metastases .
The Tukysa+Herceptin+Xeloda combination has been approved by the FDA for the treatment of advanced metastatic HER2-positive breast cancer.
This indication is suitable for patients with or without brain metastases. However, no studies have evaluated the efficacy of this combination in patients with brain metastases. Due to the aggressive nature of the disease, patients with brain metastases are usually excluded from clinical trials.
Pharmacokinetic analysis found that Tukysa (tucatinib) and its parent drug, ONT-993, were detected in the cerebrospinal fluid and were directly proportional to the level in plasma. There are 18 patients in the study, and hopefully it will increase to 30.
The combination therapy of tucatinib, trastuzumab and capecitabine has been approved by the FDA for the treatment of advanced metastatic HER2-positive breast cancer, as well as those diagnosed with brain metastases patient.
But no studies have really evaluated this combination in pia mater disease. In fact, in most clinical trials, leptomeningeal disease is often excluded from research due to its aggressiveness.
In this study, the first 15 patients were evaluated, and the pharmacokinetics in CSL and plasma were evaluated. It was found that Tukysa (Tucatinib) and its parent drug ONT-993 were both detected in CSF and were directly proportional to the level in plasma. This is the first study to evaluate tucatinib and its maternal metabolites in CSF.
Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
